Mitsubishi Tanabe Pharma Corporation announced earnings results for the nine months ended December 31, 2017. For the nine months, the company reported sales revenue JPY 339.3 billion against JPY 324.3 billion a year ago. Core operating profit was JPY 69.7 billion against JPY 79.9 billion a year ago. Operating profit was JPY 68.4 billion against JPY 79.7 billion a year ago. Profit before income tax was JPY 70,236 million compared with JPY 81,488 million a year ago. Profit for the period was JPY 49,377 million compared with JPY 58,541 million a year ago. Net profit attributable to owners of the company was JPY 52.1 billion against JPY 60.1 billion a year ago. Basic earnings per share were JPY 92.90 compared with JPY 107.30 a year ago. Net cash flows from operating activities were JPY 45,174 million compared with JPY 33,912 million a year ago. Purchase of property, plant and equipment was JPY 5,929 million compared with JPY 11,901 million a year ago. Purchase of intangible assets was JPY 17,044 million compared with JPY 6,464 million a year ago.

For the fiscal year 2018, the company expects sales revenue of JPY 433.0 billion, core operating profit of JPY 80.0 billion, operating profit of JPY 81.0 billion, net profit attributable to owners of the company of JPY 63.5 billion. Profit before income tax of JPY 82,000 million.